GlassScriptPhysician profile
Simon Starosta-Rubinstein
NPI 1063647709
$16,858.43
in general payments reported to CMS, 2019-2025
67 companies · $3,180 in 2025
The $3,180 reported for 2025 was more than what 80% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,824 · 2020: $1,423 · 2021: $3,007 · 2022: $2,252 · 2023: $2,275 · 2024: $2,898 · 2025: $3,180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,757 · Education: $596.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,756.62 |
| Education | $595.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,541.58 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $1,043.75 | 2019-2025 | Ingrezza, Ongentys |
| Ucb, INC. | $833.22 | 2019-2024 | Nayzilam, Briviact |
| Lilly USA, LLC | $818.00 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Biogen, INC. | $712.15 | 2019-2025 | Vumerity, Tysabri, Skyclarys |
| Abbvie INC. | $712.13 | 2020-2025 | Duopa, Qulipta |
| Mallinckrodt Hospital Products INC. | $655.31 | 2020-2025 | Acthar |
| Argenx US, INC. | $598.58 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Acadia Pharmaceuticals INC | $592.17 | 2019-2025 | Nuplazid |
| Pfizer INC. | $545.26 | 2021-2025 | |
| Eisai INC. | $541.17 | 2021-2025 | |
| Sk Life Science, INC. | $520.91 | 2020-2025 | |
| Amneal Pharmaceuticals LLC | $507.62 | 2019-2025 | Rytary, Crexont, Ongentys |
| Kyowa Kirin, INC. | $410.84 | 2019-2024 | Nourianz |
| Amgen INC. | $388.61 | 2019-2025 | Uplizna |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simon Starosta-Rubinstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.